Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Apr 21;21(8):e426-e436.
doi: 10.4244/EIJ-D-24-00933.

Outcomes of complex, high-risk percutaneous coronary intervention in patients with severe aortic stenosis: the ASCoP registry

Claudio Montalto  1   2 , Andrea R Munafò  1 , Francesco Soriano  1 , Ketina Arslani  3   4 , Stephanie Brunner  5 , Sarah Verhemel  6 , Ottavia Cozzi  7 , Antonio Mangieri  7 , Andrea Buono  8 , Mattia Squillace  9 , Stefano Nava  1 , José Luis Díez Gil  10 , Andrea Scotti  11 , Marco Foroni  12 , Giuseppe Esposito  1 , Alessandro Mandurino-Mirizzi  13 , David Bauer  14 , Benjamin De Ornelas  8 , Pablo Codner  15 , Kerstin Piayda  16 , Italo Porto  17 , Federico De Marco  18 , Horst Sievert  16 , Ran Kornowski  15 , Petr Tousek  14 , Dionigi Fischetti  13 , Azeem Latib  11 , Jorge Sanz Sanchez  10 , Diego Maffeo  8 , Francesco Bedogni  9 , Bernhard Reimers  7 , Damiano Regazzoli  7 , Nicolas Van Mieghem  6 , Lars Sondergaard  19 , Francesco Saia  12 , Stefan Toggweiler  5 , Ole De Backer  3   20 , Jacopo A Oreglia  1
Affiliations
Clinical Trial

Outcomes of complex, high-risk percutaneous coronary intervention in patients with severe aortic stenosis: the ASCoP registry

Claudio Montalto et al. EuroIntervention. .

Abstract

Background: There is a lack of evidence to guide treatment of patients with a concomitant indication for transcatheter aortic valve implantation (TAVI) and complex, high-risk percutaneous coronary intervention (PCI).

Aims: We aimed to assess different strategies of PCI timing in this high-risk TAVI cohort.

Methods: The ASCoP registry retrospectively included patients with a clinical indication for both TAVI and PCI with at least 1 criterion of complex or high-risk PCI. The primary endpoint was a composite of all-cause death and unplanned rehospitalisation for cardiovascular causes. The secondary endpoint was a composite of all-cause death, stroke, acute myocardial infarction, major bleeding, major vascular complication and unplanned revascularisation. Multivariable analysis was used to adjust for possible confounders.

Results: A total of 519 patients were included: 363 (69.9%) underwent staged procedures and 156 (30.1%) concomitant TAVI and PCI. After 441 (interquartile range 182-824) days, the primary endpoint occurred in 151 (36.5%) cases, without any significant difference between the 2 groups (p=0.98), while the secondary endpoint occurred more frequently in the concomitant group (n=36 [25.8%] vs n=57 [17.4%]; p=0.014).

Conclusions: In patients undergoing TAVI and complex/high-risk PCI, a concomitant strategy is associated with a higher rate of adverse events and increased procedural risk. (ClinicalTrials.gov: NCT05750927).

PubMed Disclaimer

Conflict of interest statement

K. Arslani has received research grants from the Swiss Academy of Medical Sciences, the Gottfried and Julia Bangerter-Rhyner-Foundation, and the Swiss National Science Foundation (P500PM_202963), Switzerland, outside the submitted work. The other authors have no conflicts of interest relevant to the present work to declare.

References

    1. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi L, De Bonis, De Paulis, Delgado V, Freemantle N, Haugaa KH, Jeppsson A, Jüni P, Pierard L, Prendergast BD, Sádaba JR, Tribouilloy C, Wojakowski W. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. EuroIntervention. 2022;17:e1126–96. - PMC - PubMed
    1. Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, 3rd, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O’Gara PT, Rigolin VH, Sundt TM, 3rd, Thompson A, Toly C. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143:e72–227. - PubMed
    1. Massussi M, Adamo M, Rosati F, Chizzola G, Metra M, Tarantini G. Coronary artery disease and TAVI: Current evidence on a recurrent issue. Catheter Cardiovasc Interv. 2023;101:1154–60. - PubMed
    1. Abdel-Wahab M, Zahn R, Horack M, Gerckens U, Schuler G, Sievert H, Naber C, Voehringer M, Schäfer U, Senges J, Richardt G. Transcatheter aortic valve implantation in patients with and without concomitant coronary artery disease: comparison of characteristics and early outcome in the German multicenter TAVI registry. Clin Res Cardiol. 2012;101:973–81. - PubMed
    1. Rheude T, Costa G, Ribichini FL, Pilgrim T, Amat Santos, De Backer, Kim WK, Ribeiro HB, Saia F, Bunc M, Tchétché D, Garot P, Mylotte D, Burzotta F, Watanabe Y, Bedogni F, Tesorio T, Tocci M, Franzone A, Valvo R, Savontaus M, Wienemann H, Porto I, Gandolfo C, Iadanza A, Bortone AS, Mach M, Latib A, Biasco L, Taramasso M, Zimarino M, Tomii D, Nuyens P, Sondergaard L, Camara SF, Palmerini T, Orzalkiewicz M, Steblovnik K, Degrelle B, Gautier A, Del Sole, Mainardi A, Pighi M, Lunardi M, Kawashima H, Criscione E, Cesario V, Biancari F, Zanin F, Esposito G, Adam M, Grube E, Baldus S, De Marzo, Piredda E, Cannata S, Iacovelli F, Andreas M, Frittitta V, Dipietro E, Reddavid C, Strazzieri O, Motta S, Angellotti D, Sgroi C, Xhepa E, Kargoli F, Tamburino C, Joner M, Barbanti M. Comparison of different percutaneous revascularisation timing strategies in patients undergoing transcatheter aortic valve implantation. EuroIntervention. 2023;19:589–99. - PMC - PubMed

Publication types

Associated data

LinkOut - more resources